Objective: To present a systematic review assessing the efficacy and safety of mirabegron for overactive bladder (OAB). Materials and Methods: A literature search was performed using the Cochrane Library, MEDLINE, EMBASE and Science Citation Index Expanded. The literature reviewed included meta-analyses, randomized and nonrandomized prospective studies. We utilized mean difference (MD) to measure the mean number of incontinence episodes and the mean number of micturitions, and OAB questionnaire (OAB-q) and odds ratio (OR) to measure adverse events rates. We used the Cochrane Collaboration's Review Manager 5.1 software for statistical analysis. Results: We identified six publications that strictly met our eligibility criteria. Meta-analysis of extractable data showed that mirabegron was more effective than placebo in treating OAB despite different drug dosages in the efficacy end points: mean number of incontinence episodes per 24 h (MD -0.54; 95% CI -0.63, -0.45; p = 0.001), mean number of micturitions per 24 h (MD -0.55; 95% CI -0.63, -0.47; p = 0.001), OAB-q (MD -4.49; 95% CI -6.27, -2.71; p = 0.001) and adverse events (OR 0.99; 95% CI 0.83, 1.19; p = 0.92). When compared to tolterodine, mirabegron was more effective in terms of mean number of incontinence episodes per 24 h (MD -0.25; 95% CI -0.43, -0.06; p = 0.009). However, there were no differences between mirabegron and tolterodine in mean number of micturitions per 24 h (MD -0.17; 95% CI -0.35, 0.01; p = 0.07) and OAB-q (MD -1.09; 95% CI -2.51, 0.33; p = 0.13). Mirabegron also had a lower adverse reaction rate (OR 0.9; 95% CI 0.8, 1.0; p = 0.04). Conclusions: In this diverse population, mirabegron was an effective and safe pharmacologic therapy for OAB.

Keywords:
Mirabegron, Overactive bladder, Adrenergic beta-3 receptor agonists, Lower urinary tract symptoms, Meta-analysis
1.
Abrams P, Cardozo L, Fall M, et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
2.
Abrams P, Chapple C, Khoury S, Roehrborn C, De la Rosette J: Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2013;189:S93-S101.
3.
Milsom I, Abrams P, Cardozo L, Roberts R, Thüroff J, Wein A: How widespread are the symptoms of an overactive bladder and how are they managed? A populationbased prevalence study. BJU Int 2001;87:760-766.
4.
Stewart WF, Van Rooyen JB, Cundiff GW, et al: Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336.
5.
Irwin DE, Milsom I, Hunskaar S, et al: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1314; discussion 1314-1315.
6.
Symonds T: A review of condition-specific instruments to assess the impact of urinary incontinence on health-related quality of life. Eur Urol 2003;43:219-225.
7.
Tyagi P, Tyagi V: Mirabegron, a beta(3)-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010;13:713-722.
8.
Tyagi P, Tyagi V, Chancellor M: Mirabegron: a safety review. Expert Opin Drug Saf 2011;10:287-294.
9.
Sanford M: Mirabegron: a review of its use in patients with overactive bladder syndrome. Drugs 2013;73:1213-1225.
10.
Andersson KE: Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 2009;1:71-83.
11.
Takasu T, Ukai M, Sato S, et al: Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321:642-647.
12.
Chapple CR, Dvorak V, Radziszewski P, et al: A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 2013;24:1447-1458.
13.
Chapple CR, Amarenco G, Lopez Aramburu MA, et al: A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013;32:1116-1122.
14.
Herschorn S, Barkin J, Castro-Diaz D, et al: A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-320.
15.
Khullar V, Amarenco G, Angulo JC, et al: Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-295.
16.
Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S: Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-1395.
17.
Chapple CR, Kaplan SA, Mitcheson D, et al: Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305.
18.
Higgins JP, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Wiley Online Library 2008.
19.
Michel MC, Ochodnicky P, Homma Y, Igawa Y: Beta-adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 2011;131:40-49.
20.
Novack GD, Lewis RA, Vogel R, et al: Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther 2013;29:674-680.
21.
Caremel R, Loutochin O, Corcos J: What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder? Int Urogynecol J 2014;25:165-170.
22.
Cui Y, Zong H, Yang C, Yan H, Zhang Y: The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 2014;46:275-284.
23.
Wagg A, Majumdar A, Toozs-Hobson P, Patel AK, Chapple CR, Hill S: Current and future trends in the management of overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:81-94.
24.
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-562.
25.
Paquette A, Gou P, Tannenbaum C: Systematic review and metaanalysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011;59:1332-1339.
26.
Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM: Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012;62:1040-1060.
27.
Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM: The management of overactive bladder syndrome. BMJ 2012;344:e2365.
28.
Nitti VW, Khullar V, van Kerrebroeck P, et al: Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-632.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.